Cefditoren sodium |
| Catalog No.GC64043 |
Cefditoren sodium (ME 1206) is a broad-spectrum, third-generation, oral cephalosporin antibacterial with enhanced stability against many common β lactamases.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 104146-53-4
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Cefditoren sodium (ME 1206) is a broad-spectrum, third-generation, oral cephalosporin antibacterial with enhanced stability against many common β lactamases. Cefditoren sodium has activity against Gram-negative organisms and Gram-positive organisms. Cefditoren sodium can be used in the research of infection diseases such as acute exacerbations of chronic bronchitis, community-acquired pneumonia (CAP), streptococcal pharyngitis/tonsillitis, or uncomplicated skin and skin structure infections[1][2].
Cefditoren (sodium) shows good activity against pneumoniae, S. pyogenes, Staphylococcus aureus, H. influenzae and H. parainfluenzae, M. catarrhalis[1]. Organism MIC50 (mg/L) MIC90 (mg/L) susceptible (%) Gram-positive organisms Streptococcus pneumoniae(untyped)a 0.015-0.25 0.12-1 PS ≤0.008-0.03 0.015-0.25 99-100 PI 0.06-0.5 0.25-0.5 94-100 PR 0.25-1 0.5-2 7-100 S. pyogenes ≤0.008-0.03 0.015-0.03 100 Staphylococcus aureus (MS) 0.12-0.5 0.5-1 50-100 Gram-negative organisms Haemophilus ≤0.008-≤0.03 0.015-0.13 influenzae (untyped)b β-Lactamase + ≤0.008-0.03 0.015-0.06 100 β-Lactamase - ≤0.008-0.03 0.015-0.06 100 H. parainfluenzaeb ≤0.03 0.06 Moraxella 0.03-0.5 0.25-1 96 catarrhalis (untyped)b β-Lactamase + ≤0.03-0.25 0.12-0.5 100 β-Lactamase - ≤0.008-0.03 0.015-0.06 100 a Including PS, PI and PR strains.b Including both β-lactamase-positive and -negative strains.MIC50/90=mean minimum inhibitory concentrations required to inhibit the growth of 50% or 90% of bacterial strains; MS=susceptible to meticillin; PI=intermediate susceptibility to penicillin; PR=resistant to penicillin; PS=susceptible to penicillin.
Pharmacokinetics in mice[1]: Cefditoren (mg/kg) C0 (µg/ml) t1/2 (h) AUClast (µg× h/ml) Tlast (h) 6.25 53.0 0.9 30.4 6 12.5 168.4 1.1 64.1 8 25 232.5 0.9 101.3 8 50 290.6 1.1 124.4 8
[1]. Wellington K, et al. Cefditoren pivoxil: a review of its use in the treatment of bacterial infections. Drugs. 2004;64(22):2597-618.
[2]. Cafini F, et al. Enhanced in vivo activity of cefditoren in pre-immunized mice against penicillin-resistant S. pneumoniae (serotypes 6B, 19F and 23F) in a sepsis model. PLoS One. 2010 Aug 10;5(8):e12041.
| Cas No. | 104146-53-4 | SDF | |
| Formula | C19H17N6NaO5S3 | M.Wt | 528.56 |
| Solubility | DMSO : 31.25 mg/mL (59.12 mM; ultrasonic and warming and heat to 60°C) | Storage | 4°C, away from moisture |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 1.8919 mL | 9.4597 mL | 18.9193 mL |
| 5 mM | 0.3784 mL | 1.8919 mL | 3.7839 mL |
| 10 mM | 0.1892 mL | 0.946 mL | 1.8919 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 31 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *